- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Circulating levels of brodalumab tied to therapy outcomes in psoriasis patients: Study
Denmark: Circulating brodalumab level is a factor associated with clinical treatment response in patients with psoriasis, states case series study results published in JAMA Dermatology. Monitoring levels of circulating brodalumab in psoriasis patients may help clinical decision-making towards the prevention of ineffective therapy, the study suggests.
Psoriasis is a serious global problem, affecting at least 100 million individuals of all ages, and in all countries. With recent advances, many possible treatment modalities in psoriasis management are available but estimating the ideal treatment choice for each patient is a challenge. There are no validated, clinically useful biomarkers and so treatment modalities are generally applied on a trial-and-error basis. Brodalumab, a human monoclonal antibody to the interleukin-17A receptor, which acts as an immunosuppressant may be considered as first-line therapy in Psoriasis and also as rescue therapy in patients refractory to treatment.
A multicenter case series study was performed by Christian Enevold, Copenhagen University Hospital, Denmark, and colleagues to assess whether brodalumab levels are associated with clinical response, as measured by reductions in Psoriasis Area and Severity Index (PASI), and can be used as a marker of long term response.
They measured trough levels of circulating brodalumab and antidrug antibodies in 20 consecutive patients with prior failure to anti–IL-17A therapy, who had baseline PASI score of 6 or higher and had not received concomitant systemic treatment for psoriasis,
Researchers administered Brodalumab, 210 mg, at weeks 0, 1, 2, and then every 2 weeks to patients and conducted patient visits after 4 and 12 weeks of therapy. Patients maintaining PASI 75 response were followed up for up to 52 weeks.
Data results after 12 weeks of therapy showed that,
• Patients with quantifiable levels of brodalumab (≥0.05 μg/mL) experienced significantly higher PASI reductions than those without.
• 4 of 5 patients (80%) not achieving PASI 75 had subquantifiable drug levels (<0.05 μg/mL), notably this was seen for only 3 of 14 PASI 75 responders (21%)
• None of 7 patients (35%) with subquantifiable brodalumab levels were associated with a lack of response at a statistically significant level.
• Antibrodalumab antibodies were not detected in any of the samples.
Researchers conclude that circulating trough levels of brodalumab were associated with concomitant response, and subquantifiable brodalumab levels after 12 weeks of therapy identified long-term nonresponders, at least in patients with previous response failure to other biological treatments.
Reference:
Enevold C, Loft N, Bregnhøj A, et al. Circulating Brodalumab Levels and Therapy Outcomes in Patients With Psoriasis Treated With Brodalumab: A Case Series. JAMA Dermatol. Published online June 01, 2022. doi:10.1001/jamadermatol.2022.1863
BDS
Dr. Hiral patel (BDS) has completed BDS from Gujarat University, Baroda. She has worked in private dental steup for 8years and is currently a consulting general dentist in mumbai. She has recently completed her advanced PG diploma in clinical research and pharmacovigilance. She is passionate about writing and loves to read, analyses and write informative medical content for readers. She can be contacted at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751